India Multiple Myeloma Market Assessment, By Drug Class, By Disease Type, By Distribution Channel, By Region, Opportunities and Forecast, FY2019-FY2033F

India multiple myeloma market is projected to witness a CAGR of 7.25% during the forecast period FY2026-FY2033, growing from USD 192.08 million in FY2025 to USD 336.25 million in FY2033. The India multiple myeloma market is witnessing rapid growth due to the rising prevalence of blood cancers and increasing awareness initiatives. Advancements in targeted therapies like anti-CD38 monoclonal antibodies are improving treatment outcomes and expanding patient access. Additionally, the strengthening healthcare infrastructure in South India is further propelling regional market growth.

For example, medical professionals at AIIMS, Delhi are currently working on creating an affordable antibody-based adaptive cellular therapy aimed at treating multiple myeloma, a type of blood cancer. This innovative therapy is anticipated to enhance the affordability and accessibility of advanced treatments such as CAR-T cell therapies for patients in India.

Rising Cancer Prevalence and Growing Awareness to Accelerate Market Growth

The increasing incidence of blood cancers, particularly multiple myeloma, is a major factor fueling market expansion in India. Multiple myeloma often remains underdiagnosed in earlier stages; however, with enhanced public health awareness, early diagnosis rates are improving. Additionally, educational campaigns initiated by hospitals and healthcare organizations are promoting awareness about hematological malignancies, leading to higher demand for advanced therapies. The growing healthcare expenditure and the expanding network of cancer specialty centers are also contributing to broader treatment accessibility. These factors are creating a robust environment for the adoption of novel drug classes like immunomodulators and proteasome inhibitors. For instance, in August 2024, the Kidwai Memorial Institute of Oncology in Bangalore (KMIO) organized 'Myeloma Matters: An International Symposium on Multiple Myeloma' to discuss the challenges and advancements in the treatment of patients.

Advancements in Anti-CD38 Monoclonal Antibody Therapies Driving Market Expansion

The segment of anti-CD38 monoclonal antibody therapies is witnessing significant growth in India's multiple myeloma market. These therapies have shown greater effectiveness and improved patient outcomes when compared to conventional treatment methods, especially in cases of relapsed or refractory multiple myeloma. Indian pharmaceutical firms are increasingly dedicating efforts to the research, development, and marketing of biosimilars and generics aimed at CD38, thereby improving affordability and access. Furthermore, the Indian Council of Medical Research (ICMR) has emphasized monoclonal antibody therapies in its revised treatment protocols for multiple myeloma, which is expected to enhance the adoption of this segment. For instance, Dr. Reddy's Laboratories, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., announced a licensing agreement in February 2025 with Shanghai Henlius Biotech, Inc. for the development and commercialization of HLX15, Henlius's investigational biosimilar candidate for daratumumab, marketed as Darzalex(R) and Darzalex Faspro(R).

Strong Regional Growth in South India Due to Rising Healthcare Infrastructure

The southern region of India, especially Tamil Nadu and Karnataka, is becoming a significant area of growth for the multiple myeloma market. This region features a sophisticated healthcare system, heightened patient awareness, and a multitude of specialized cancer hospitals that provide innovative treatment options. Furthermore, the rise in healthcare investments from both state governments and the private sector is enhancing cancer care services. South India's prompt adoption of advanced treatments, such as immunotherapies and targeted biologics, is propelling the expansion of the multiple myeloma pharmaceutical market. A notable advancement in oncology care is the establishment of India's first AI-Precision Oncology Centre (POC) at Apollo Cancer Centre in Bengaluru, which aims to support oncologists, patients, and caregivers in achieving optimal treatment outcomes through the effective use of artificial intelligence.

Future Market Scenario (FY2026 - FY2033F)

India multiple myeloma market is expected to witness robust growth in the coming years, driven by increasing disease awareness, rising healthcare spending, and the growing availability of innovative treatment options. Advances in targeted therapies, such as anti-CD38 monoclonal antibodies and proteasome inhibitors, are improving patient outcomes and expanding treatment accessibility. Furthermore, government initiatives to enhance cancer care infrastructure and early diagnosis programs are strengthening market dynamics. Collaborations between domestic and international pharmaceutical companies to develop biosimilars and affordable therapies will also significantly contribute to market expansion. With a rising elderly population and greater emphasis on specialized oncology centers, the India multiple myeloma market is poised for substantial growth, offering new opportunities for pharmaceutical innovation and patient care advancement.

Key Players Landscape and Outlook

Key players in the multiple myeloma industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For instance, in a major advancement for cancer treatment, PGI is set to commence clinical trials of CAR T-cell therapy for patients with multiple myeloma. This initiative is part of a broader national effort and provides renewed hope for those fighting cancer. The ethics committee has granted approval for the trials at the institute, which is one of the locations involved in the multi-centric study.